Vericel (VCEL) Research & Development (2010 - 2026)
Vericel (VCEL) posted Research & Development of $7.5 million for Q2 2026, down 7.54% sequentially from $8.1 million in Q1 2026, and up 11.32% YoY from $6.7 million in Q2 2025.
Analysis
Vericel (VCEL) Research & Development (2010 - 2026) Analysis & Trends
Vericel has reported Research & Development for 17 years, with the latest figure at $7.5 million in Q2 2026.
- Quarterly Research & Development rose 11.32% year-over-year to $7.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $29.2 million (up 16.63% YoY) and the FY2025 annual result came in at $27.6 million, up 11.15% from the prior year.
- Research & Development fell to $7.5 million in Q2 2026 per VCEL's latest filing, from $8.1 million in the prior quarter.
- Over five years, Research & Development peaked at $8.1 million in Q1 2026 and troughed at $4.8 million in Q2 2022.
- A 5-year average of $6.1 million and a median of $5.9 million in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 47.33% in 2025, down 8.58% in 2025.
- Over 5 years, Research & Development stood at $5.2 million in 2022, then retreated by 6.56% to $4.9 million in 2023, then advanced by 0.45% to $4.9 million in 2024, then soared by 47.33% to $7.3 million in 2025, then climbed by 3.31% to $7.5 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $7.5 million, $8.1 million, and $7.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -486.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 651.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 394.92 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 612.28 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 97.90 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 7.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.49 Mn |
| Mar 31, 2026 | 8.10 Mn |
| Dec 31, 2025 | 7.25 Mn |
| Sep 30, 2025 | 6.32 Mn |
| Jun 30, 2025 | 6.73 Mn |
| Mar 31, 2025 | 7.26 Mn |
| Dec 31, 2024 | 4.92 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 7.36 Mn |
| Mar 31, 2024 | 6.42 Mn |
| Dec 31, 2023 | 4.90 Mn |
| Sep 30, 2023 | 5.68 Mn |
| Jun 30, 2023 | 5.25 Mn |
| Mar 31, 2023 | 5.21 Mn |
| Dec 31, 2022 | 5.25 Mn |
| Sep 30, 2022 | 5.05 Mn |
| Jun 30, 2022 | 4.79 Mn |
| Mar 31, 2022 | 4.86 Mn |
| Dec 31, 2021 | 3.92 Mn |
| Sep 30, 2021 | 4.28 Mn |